FTC诉阿特维斯生物仿制药案的命运——FTC诉阿特维斯的判决是否适用于品牌药和生物仿制药制造商之间的反向专利和解?

{"title":"FTC诉阿特维斯生物仿制药案的命运——FTC诉阿特维斯的判决是否适用于品牌药和生物仿制药制造商之间的反向专利和解?","authors":"N. Ho","doi":"10.1089/blr.2022.29274.nho","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":55354,"journal":{"name":"Biotechnology Law Report","volume":" ","pages":""},"PeriodicalIF":0.2000,"publicationDate":"2022-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The Fate of FTC v. Actavis, Inc. in the Biosimilar Context—Does and Should the FTC v. Actavis Decision Apply to Reverse Patent Settlements Between Brand Drug and Biosimilar Manufacturers?\",\"authors\":\"N. Ho\",\"doi\":\"10.1089/blr.2022.29274.nho\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":55354,\"journal\":{\"name\":\"Biotechnology Law Report\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.2000,\"publicationDate\":\"2022-07-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biotechnology Law Report\",\"FirstCategoryId\":\"5\",\"ListUrlMain\":\"https://doi.org/10.1089/blr.2022.29274.nho\",\"RegionNum\":4,\"RegionCategory\":\"生物学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"BIOTECHNOLOGY & APPLIED MICROBIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biotechnology Law Report","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1089/blr.2022.29274.nho","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}